A Biodegradable Stent with Surface Functionalization of Combined-Therapy Drugs for Colorectal Cancer

DOI:
10.1002/adhm.201801213

Document Version
Accepted author manuscript

Link to publication record in Manchester Research Explorer

Citation for published version (APA):

Published in:
Advanced Healthcare Materials

Citing this paper
Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights
Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy
If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.
Silk fibroin-based biodegradable intestinal stents loaded with combined-therapy drugs for colorectal cancer

Xusheng Xie a,1, Xiaobin Zheng b,1, Zhifen Han c, Yufeng Chen b, Zhuzhao Zheng a, Bin Zheng b, Xiaowen He b, Yongfeng Wang a, David L Kaplan d, Yi Li e, Gang Li a,*, Xiaoqin Wang a,**, Ping Lan b,***

aNational Engineering Laboratory for Modern Silk, College of Textile and Clothing Engineering, Soochow University, Suzhou 215123, P.R.China

bDepartment of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China

cDepartment of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

dDepartment of Biomedical Engineering, Tufts University, 4 Colby St, Medford, MA 02155, USA

eSchool of Materials, The University of Manchester, Manchester M13 9PL, UK

*Corresponding authors’ email: tcligang@suda.edu.cn; wangxiaoqin@suda.edu.cn; lpzm@yahoo.com

1These authors contributed to this manuscript equally.
Abstract: In-stent restenosis caused by tumor ingrowth is a major problem for patients undergoing stent placement because conventional stents often lack sustainable anti-tumor capabilities. The aim of this work was to develop a silk fibroin (SF)-based polydioxanone (PDO) stent with a combination of weft-knitting and electrospinning technologies to address mechanical, biodegradation and drug delivery requirements. The inner layer of the stent was knitted from PDO monofilaments and SF yarns. In order to improve treatment effectiveness, a combination of therapeutic drugs, i.e., curcumin (CUR) and 5-fluorouracil (5-FU), were dissolved with Poly(ethylene glycol) (PEG) in SF solution at three concentrations (0.15/0.25, 0.3/0.5 and 0.45/0.75 wt% in SF solution), and electrospun onto the weft-knitted SF/PDO stent. The morphology, chemical structure, mechanical properties and in vitro drug release profiles of the drug-loaded devices were characterized. The anti-tumor efficacy was assessed in vitro and in vivo using a human colorectal cancer cell line HCT116, normal cells NCM460 and tumor-bearing BALB/c nude mice. The results showed that the release of dual drugs from the three membranes lasted 210 to 400 hours. In vitro and in vivo studies on the membrane-coated stents demonstrated improved anti-tumor effects for the CUR/5-FU dual drug system which can be attributed to cell cycle arrest in the S phase in association with induced apoptosis in tumor cells by blocking Stat3 and NF-κB signaling pathways, suggesting potential in the treatment of colorectal cancer.

Keywords: colorectal cancer; weft-knitted stent; curcumin; 5-fluorouracil; silk fibroin; polydioxanone.
Silk fibroin-based biodegradable intestinal stents loaded with combined-therapy drugs for colorectal cancer

1. Introduction

Colon and rectal cancer (CRC) are some of the most serious cancers in terms of both incidence and mortality globally [1]. Intestinal obstruction and stenosis are main symptoms of CRC patients, with mortality over 80-90% within five years without effective treatment [2, 3]. In the clinic, stent placement in combination with radio-chemotherapy is an effective palliative treatment for colorectal cancer patients with advanced acute obstruction, high emergent surgical risk, multiple transfer rate and/or in poor general health [4]. However, postoperative complications and in-stent restenosis caused by tumor ingrowth are major problems for patients undergoing stent displacement [4-6]. However, conventional stents made from metal materials only meet the requirements of mechanical expansion and temporary treatment [5, 6]. Therefore, development of new intestinal stents with good biocompatibility, degradability and drug delivery functions is of particular importance [7]. The concept of this type of intestinal stent with drug delivery functions is shown in Fig. 1, where the stenosis site can be expanded and the tumor site can be locally treated by drugs released from membranes on the stent.

5-Fluorouracil (5-FU) has been used for the treatment of patients with CRC [2], however, the short half-life (10-20 minutes), low utilization rate (10-30%), poor sensitivity, and toxicity to normal cells [8, 9] are problems. Hence, development of a device that can encapsulate and stabilize 5-FU is important for the improved utilization of the drug to achieve desired clinical outcomes. In previous studies, a drug-loaded polydioxanone weft-knitted stent was developed to treat CRC by slow releasing 5-FU [2, 3]. The half maximal inhibitory concentration (IC\textsubscript{50}) and the median lethal dose (LD\textsubscript{50}) demonstrated that these drug-loaded membranes had better anti-tumor effects than pure 5-FU due to the sustainable drug
releasing property of the coated membranes on the stent [2, 3]. A 5-FU/paclitaxel loaded esophageal stent was also developed for the treatment of esophageal cancer and these treatment modalities were evaluated in vivo after implantation into the porcine esophagus [10]. The results illustrated that the drug-loaded stents had a dual function as a local drug delivery device, which provided potential treatment with high efficacy and reduced systematic toxicity for the treatment of esophageal cancer.

Combination therapy uses more than one medication or modality, with the major benefit of reduction in development of drug resistance, since a pathogen or tumor is less likely to have resistance to multiple drugs simultaneously. New evidence suggests that the combined use of chemopreventive agents has an inhibitory effect on CRC [11]. Curcumin (diferuloylmethane, 1,7-bis(4-hydroxy-3-methoxy-phenyl)-1,6-heptadiene-3,5-dione) (CUR), obtained from the spice turmeric, exhibits numerous biological activities including anti-tumor, anti-inflammatory and anti-angiogenesis, as well as inhibiting the proliferation and metastasis of CRC [12]. However, CUR has poor water solubility and low bioavailability in vivo, which limited clinical applications. One strategy to address this problem is to combine CUR with 5-FU, and recent studies have demonstrated the coordinative and improved anti-tumor effect of CUR and 5-FU in chemotherapeutic treatment [13]. Toden et al. [13] carried out an in vitro and vivo study to examine the effects of CUR and 5-FU individually, and in combination. Both CUR and 5-FU were dissolved in dimethyl sulfoxide (DMSO) and diluted to appropriate concentrations with tissue culture medium, and then intraperitoneally injected into mice daily for 40 days. The results demonstrated that CUR-mediated sensitization to 5-FU in CRC cells occurred through the suppression of the epithelial-mesenchymal transition (EMT) and polycomb repressive complex (PRC), which are regulated by microRNAs. This study provided evidence for the use of CUR as an adjunct to 5-FU-based chemotherapy in CRC. However, this is still a traditional chemotherapeutic treatment in which the disadvantages of the dual drugs were illustrated. The development of a new drug delivery system in which CUR and 5-FU are incorporated and function simultaneously, with a goal towards medical device needs, was the focus of
the present study. Our hypothesis was that the combined use of the two drugs may not only improve the utilization, sensitivity and anti-tumor effect of the device, but also reduce the side effects of 5-FU.

Silk fibroin (SF), a natural protein polymer with excellent processability, mechanical properties, biocompatibility and biodegradability, has been studied for many biomedical uses [14, 15]. SF can be processed into fibers, gels, membranes, micro/nano-particles and porous scaffolds, which have been used in tissue engineering [16-19], enzyme immobilization and drug controlled release [20-22]. The biosafety and biocompatibility of SF has been demonstrated in previous studies [23, 24], as well as in FDA approved medical devices. SF can also carry and release CUR effectively during enzymatic digestion [20, 25, 26]. Electrospinning technology has been widely used to fabricate micro or nano fibrous materials for drug delivery applications [25-29]. Importantly, poorly water-soluble drugs loaded into water-soluble and water-insoluble fibrous SF fibers using electrospinning can be useful in tissue engineering and topical drug administration goals [26, 30, 31].

The aim of the present study was to develop a SF-modified polydioxanone (PDO) stent with a combination of weft-knitting and electrospinning technologies. SF/PDO stents were first weft-knitted, and then drug-loaded electro-spun SF membranes were produced by adding CUR and 5-FU into the SF spinning solution for sustained drug release. The morphology, secondary structure, and in vitro drug release properties of the coated membranes were analyzed. The anti-tumor efficacy was assessed in vitro and in vivo using the human colorectal cancer cell line HCT116, normal human colon mucosal epithelial cell line NCM460, and tumor-bearing BALB/c nude mice.

2. Materials and Methods

2.1 Experimental design (Fig. 2)

PDO monofilament (Samyang Co., Korea) with a linear density of 105 tex and SF multifilament with a linear density of 5 tex were knitted into a tubular stent 60 ± 2 mm long and 25 mm in diameter using a
circular weft-knitting machine (Model ST-06SL), needle number 22/44 needles, circular type, machine diameter: 30 mm, gauge: 7 (Shanghai Sailing Ltd. Co., China). Generally, the length and diameter of the stents can be adjusted according to computed tomography (CT) assessments of the intestine with stenosis or obstructions in patients. CT is a diagnostic imaging test used to create three dimensional and detailed images of internal organs, bones, and soft tissue like intestine and blood vessels. CT scanning is often the best method for detecting different cancers, since the images allow confirmation of the presence, size and location of a tumor. In this study, the stent size was set based on commercially available metal stents commercially [32]. Drug-loaded SF fibrous membranes were electrospun onto the surface of the prepared PDO/SF stents (Figs. 2c, d). Subsequently, disk-shape drug-loaded membranes were cut from the stent to investigate the in vitro and in vivo anti-tumor potential using HCT116, NCM460 cells and BALB/c nude mice (Fig. 2e, 2f, 2g).

2.2 Materials

Anticancer compounds, CUR and 5-FU, were obtained from Sigma (Springdale, AR, USA). PDO was purchased from Samyang Co., Korea. Poly(ethylene glycol) (PEG) with a molecular weight of 400 was purchased from Dow Chemical Company, USA. Mulberry silk was supplied by Shengzhou Xiehe silk Co., Ltd. China. Other reagents and solvents were analytical grade. HCT116 and NCM460 cells were obtained from the Cell Bank of the Chinese Academy of Science (Shanghai, China). BALB/c nude mice were supplied by the Laboratory Animal Center of Sun Yat-Sen University (Guangzhou, China).

2.3 Preparation of the CUR/5-FU membranes

SF solution at 23 wt% was prepared following a standard procedure developed in our lab, which contains steps of degumming silk, fiber dissolution by lithium bromide, dialysis to remove salt, centrifugation to remove insoluble aggregates, and determination of SF concentration [23, 24]. Three different drug loaded membranes were prepared by mixing CUR/5-FU at concentration ratios of 0.15/0.25%, 0.3/0.5% and 0.45/0.75% by weight to SF solution of 23 wt%. The above dual drugs were
dissolved into 60% PEG-400 with an Ultrasonic cell disruptor (JY92-IIDN, China) at 40% power output for 30 minutes. The mixed solution containing drugs and SF was added to a plastic syringe with a stainless steel needle (inner diameter is 0.5 mm), and the plastic syringe was placed in a high-speed rotating electrospinning machine (NEC-10, Kato Tech Co., Ltd., Japan). The voltage was set at $25 \pm 0.5$ kV, the distance between the needle tip and the roller was set at $220 \pm 5$ mm, and the injection speed of spinning solution was set at $0.2 \pm 0.05$ mL/h. All samples were vacuum-dried at $60^\circ$C for 12 hours to remove solvent before characterization.

2.4 Characterization on CUR/5-FU loaded membranes

2.4.1 Morphology and pore size distribution

The morphologies of the membranes were examined using scanning electron microscopy (SEM) (Hitachi S-4800, Japan) at an acceleration voltage of 3 kV. All films were placed in fume hood for 12 hrs, then sputter-coated with gold (E-1045, Japan Co., Ltd.) for 90s. Image J software (National Institute of Mental Health, USA) was used to measure the diameters of 30 fibers randomly chosen from the SEM images, and their mean value and standard deviation were calculated. The pore size distributions in the membranes were measured by a capillary flow porometer (Porometer 3G, Quanta chrome Instruments, USA). All tested samples were cut into round membranes with a diameter of 25 mm. During the measurement, the wetting liquid was expelled through the pores in samples. Air pressure was automatically applied on the membrane, and the air flow through the pores was accurately recorded. The actual pressure applied to the sample was measured independently.

2.4.2 Hydrophilicity test

In order to investigate the hydrophilicity of the membranes, the apparent contact angle was examined by a Krüss DSA 100 (Krüss Company, Germany) apparatus, using a sessile drop (5 µL drop of pure water)
method. The apparent static contact angle values were measured by Image J software (National Institute of Mental Health, USA).

### 2.4.3 Structural analysis

The secondary structure of the drug-loaded membranes was examined using Fourier Transform Infrared Spectroscopy (FT-IR) with a MIRacle™ attenuated total reflection (ATR) Ge crystal cell in the reflection mode (Nicolet 5700, Thermo Electron Corp, Waltham, MA). FT-IR wave numbers were set from 4000 to 400 cm\(^{-1}\) during 32 scans, with 2 cm\(^{-1}\) resolutions. The major vibration bands were attributed to specific chemical groups. The internal crystalline structure of the drug-loaded membranes was examined via an X-ray diffractometer (X’Pert-Pro MPD, PANalytical BV, Almelo, Netherlands) using a Cu Kα radiation source. Two dimensional X-ray diffraction patterns were obtained at the following irradiation settings: Cu, Kα, wave length 0.154 nm, range 5⁰ - 60⁰, 40 kV and 35 mA at a scanning rate of 5° min\(^{-1}\).

### 2.4.4 Drug release

A membrane with 4 mg of drug loading was soaked in 2 mL phosphate-buffered saline (PBS), pH=7.4, at room temperature in a tube that was placed in a shaking water bath (Shanghai Yiheng Co., China) set at 100 cycles/min. The release solution of 1 mL was collected at 0, 1, 3, 6, 9, 12, 24, 48, 72, 96, 120, 300, and 400-hour intervals, and the release solution was supplemented with 1 mL PBS after sampling. The concentration of 5-FU in the release solution was measured by High Performance Liquid Chromatography (HPLC) (1260 series, Agilent Technologies, USA) that was equipped with waters C\(_{18}\) column (250 mm × 4.6 mm, 5 µm). Prior to the sample (10 µL) injection, the release solution was filtered with 0.22 µm filters. The UV absorbance wavelength of 265 nm was used for detection. The mobile phase was composed of 90% deionized water and 10% methanol (10:90, V/V) purged at a flow rate of 1 mL/min. The concentration of 5-FU was calculated according to the standard equation
(Y=41.03X+4.432, R²=0.999. The concentration of CUR in the release solution was measured by UV absorbance at 425 nm. The release solution of 200 μL was dropped into 96-well plates and the absorbance of the solution was determined by using a microplate reader (Bio-TeK synergy H1, USA). The concentration of CUR was calculated by the standard equation (Y=26.11X-0.476, R²=0.999).

2.4.5 Cell culture and morphology

HCT116 and NCM460 cells were cultured as a monolayer at 37°C in the Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, Invitrogen) supplemented with 10% FBS (Gibco, Invitrogen) and 1% pen-strep (100 U/mL penicillin and 100 mg/mL streptomycin) (Gibco, Invitrogen) in a humidified incubator containing 5% CO₂. The culture medium was refreshed every 48 hrs and the amount of cells was counted using a Cellometer Auto T4 (Nexcelom Bioscience LLC, USA). Disk-shaped samples were cut from the membranes and placed on the bottom of 6-well plates. The membranes were either fixed to the bottom of the wells with rubber rings or not fixed (membrane floated in the medium during culture). Prior to cell seeding, the membranes were pre-sterilized under ⁶⁰Co radiation at 18 kGy (Irradiation Technology Institute of Soochow University, China). A total of 1.0×10⁵ HCT116 and NCM460 cells in 2 mL medium were added into one well of 6-well plates containing experimental samples (Control, SF membrane, CUR of IC₅₀, 5-FU of IC₅₀, CUR/5-FU of IC₅₀, CUR/5-FU loaded membrane of 0.15/0.25 wt%, 0.30/0.50 wt% and 0.45/0.75 wt%). For imaging, cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) (pH 7.4) for 5 mins at room temperature, washed three times with PBS, and kept at 4°C until use. The actin cytoskeleton and DNA were stained with rhodamine-labeled phalloidin and 4’, 6-diamidino-2-phenylindole dihydrochloride (DAPI), respectively, and observed using a Keyence BZ-X710 fluorescent microscope (Keyence, USA).

2.4.6 Cell Proliferation Assay

Both the anti-tumor effects on HCT116 cells and cytotoxicity on NCM460 cells of drug-loaded membranes were determined by MTS assay. Briefly, 5.0×10³ cells in 100 μL medium were pre-
cultivated in each well of the 96-well plates for 12 hrs and then the culture medium was replaced with
treatment medium containing experimental samples as described above. After 12, 24, 48, 72, 96 and 120
hrs incubation, the medium was aspirated and cells were washed with PBS for three times.
Subsequently, 100 μL fresh serum-free medium supplemented with 20 μL CellTiter 96® AQueous One
Solution Reagent (Promega) was added and incubated for another 3hrs. The absorbance values were
measured at 490 nm using a microplate reader (Model Synergy 2, Bio-Tek, Vermont, USA) in a dark
environment. Cell viability was calculated using Eq. (1) below:

\[
Cell\text{ }viability\text{ }() = \frac{\text{Absorbance of test groups}}{\text{Absorbance of control groups}} \times 100\%
\]  

(1)

Where the test groups were the cells subjected to different treatments, and the control groups were the
untreated cells.

2.4.7 Cell cycle and apoptosis measurement

HCT116 and NCM460 cells were seeded in 6-well plates for 12 hrs, followed by co-culturing with
experimental samples as described above. After 24 and 48 hrs co-culture, cells were harvested by
trypsinization, washed and resuspended in PBS. Then, 1.0×10^6 cells were fixed with ethanol (70%, -
20°C) by vortexing mildly and maintained at 4°C for at least 12 hrs. Thereafter, the cells were
resuspended in 1 mL PBS containing 50 μg/mL propidium iodide (PI) and 50 μg/mL RNase and
incubated in the dark for 30 min at 25°C. The stained cell samples were then read and analyzed using a
BD FACS CatoII flow cytometer (BD Biosciences, USA). For apoptosis analysis, 3.0×10^6 cells of each
experimental group were harvested, washed with PBS and resuspended in 500 μL ice-cold binding
buffer. After adding 5 μL of Annexin V-FITC and 10 μL of PI solutions, all samples were incubated in
the dark for 5 min at 4°C. The stained samples were read and analyzed using a BD FACS Cato II flow
cytometer (BD Biosciences, USA).
2.4.8 Cell Western blot analysis

HCT116 and NCM460 cells were seeded in 6-well plates for 12 hrs, followed by co-culturing with experimental samples as described above (2.4.5). After 24 hrs co-culture, cells were lysed in the RIPA buffer (50 mM Tris-HCl, pH 8.0, 150Mm NaCl, 0.5% sodium deoxycholate, 1% NP-40%, and 0.1% SDS), supplemented with 1% complete EDTA-free protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). The supernatant was separated by centrifugation at 12,000 rpm for 15 min at 4°C and the protein concentration was detected by BCA protein assay kit (Thermo Pierce, USA) using bovine serum albumin as standard. Equal amounts of the protein extracts of each sample were mixed with 5× loading buffer and denatured in the boiling water for 10 min. Next, the samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred onto polyvinylidene fluoride membranes (Bio-Rad Laboratories, Hercules, CA). Each membrane was blocked at room temperature for 2 hrs and incubated with specific primary antibodies (signal transducer and activator of transcription 3 (Stat3), Cell Signaling Technology (CST), 4904S; NF-κB P65, CST, 8242) for 4°C overnight. Then, the membranes were washed in TBST and reacted with secondary horseradish peroxidase-conjugated antibody for 1 hr at room temperature, and the immunoreactive bands were visualized using an ECL kit (Bio-Rad Laboratories).

2.4.9 Cell immunocytochemistry

Cells were treated with experimental samples for 24 hrs and plated on a glass slide. The slides were air-dried for 15 mins at room temperature and fixed with 3.7% formaldehyde. After washing, slides were incubated with a rabbit polyclonal anti-human E-cadherin IgG antibody (1/100 dilution) overnight at 4°C. The day after, slides were washed and incubated with goat anti-rabbit IgG antibody (Thermo Fisher, A-11034) (green) (1/100 dilution) for 1hr and DAPI (blue) for 5 mins at the room temperature. Cells were observed using a Keyence BZ-X710 fluorescent microscope (Keyence, USA).
2.4.10 Animal preparation

A total of 25 female BALB/c nude mice (6-8 weeks old, 20 ± 2 g) were maintained in a pathogen-free environment (temperature 23 ± 2°C and humidity 55% ± 5) on a 12-hr light, 12-hr dark cycle with food and water supplied during the whole experimental period. Animal care and surgical protocols were approved by the Animal Care Committees of Sun Yat-sen University (Guangzhou, China). All animals were treated appropriately and used in a scientifically valid and ethical manner. To establish CRC allografts for in vivo studies, 2.0×10^5 HCT116 cells were subcutaneously injected into the right side of the back of BALB/c nude mice. After ten days, all mice developed a tumor with a volume exceeding 100 mm^3. The mice were randomly separated into five groups and five mice per group according to the volume of tumor that is calculated by Eq. (2). The tumor volume and mice weight change ratios (%) were calculated using Eqs. (3) and (4), respectively.

\[
\text{Tumor volume (V)} = L \times W^2 / 2
\]  
\[
\text{Tumor volume change ratio (%)} = \left( \frac{V_2}{V_N} - 1 \right) \times 100\%
\]  
\[
\text{Mice weight change ratio (%)} = \left( \frac{W_1}{W_N} - 1 \right) \times 100\%
\]

Where V, L and W is the volume, length and width of tumors, respectively; V_1 and V_N are the tumor volume measured at first day and N days after implantation of samples, respectively; W_1 and W_N are the mouse weight measured at first day and N days after treatment of samples, respectively.

The five groups were identified as follows: (1) did not take any treatment as control; (2) implantation with pure SF membrane; (3-4) intraperitoneal injection with either (3) 5-FU or (4) CUR/5-FU solution at a median lethal dose (LD_{50}); (5) implantation with CUR/5-FU (0.30/0.50 wt%) loaded membrane. After 12 days observation, all the mice were placed under general anesthesia by intraperitoneal injection of pentobarbital sodium (30 μg/g body wt%) and the membrane were implanted into the tumor as shown in Fig. 5A. Briefly, a straight skin incision about 1 cm was performed near the tumor and subcutaneous
tissue around the tumor was separated slightly for embedding the membrane. Finally, the incision was sutured so that the tumor could be treated locally by the coating on the membrane.

### 2.4.11 H&E staining analysis

Twelve weeks after implantation, mice were euthanized and the specimens along with the adjacent tissues were collected for histological examination. All the tumors were fixed in 10% formalin solution, embedded in paraffin and sectioned at 5 μm thickness. Sections were then stained with hematoxylin and eosin (H&E) (Sigma-Aldrich, St. Louis, MO) to visualize the cell nuclei and cytoplasm. A slide of each tumor was evaluated and digital imaged at a high magnification (×50 and ×200-fold) using the Leica DM IRB inverted research microscope (Leica Microsystems, Wetzlar, Germany).

### 2.4.12 Animal xenograft western blot analysis

Tumors were lysed in RIPA buffer, supplemented with 1% complete EDTA-free protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). The supernatant was separated by centrifugation at 12,000 rpm for 15 mins at 4°C and the total protein concentration was determined by BCA protein assay kit (Thermo Pierce, USA) using bovine serum albumin as standard. Protein samples were mixed with 5× loading buffer, denatured in the boiling water for 10 min and stored at -20°C until use. Protein expression was determined as described above.

### 2.5 Statistical analysis

Each experiment was repeated three times and all data sets are expressed in terms of their mean and standard deviation. Statistical analysis was performed using one-way ANOVA. The statistical difference between two groups of data was considered to be significant when p < 0.05.
3. Results and Discussion

3.1 Morphology of membrane nanofibers

The surface morphology of the fibrous membranes and the diameter distribution of the fibers were observed by SEM and optical microscopy, respectively (Fig. 3A). The SF/PEG membranes showed smaller (1.45 ± 0.41 µm) and homogeneously distributed fiber diameters compared to the pure SF membrane. Some beads were associated with the pure SF fibers. The electrospinning process generated smooth fibers, likely due to the addition of PEG-400 which increased the viscosity of the solution, which is beneficial for the formation of uniform fibrous structure. These average diameters of the fibers in the drug-loaded membranes were higher than in the SF and SF/PEG membranes without the drugs, due to the addition of CUR/5-FU. The viscosity of spinning solutions decreased with increased content of CUR/5-FU. Since surface tension can increase with a decrease in the viscosity, either this factor or viscosity played a role in determining the diameter of the electrospun fibers [33]. However, the electrical conductivity of spinning solutions increased with increase content of CUR/5-FU. Increasing the electrical conductivity of spinning solutions can promote decreased fiber diameter. The diameter of the fibers decreased from 2.74 ± 0.77 µm to 1.73 ± 0.54 µm, when the drug loading of CUR/5-FU was increased to 0.3 wt% and 0.5 wt%, respectively. While the drug loading of CUR and 5-FU increased to 0.45 wt% and 0.75 wt%, the diameter of the fibers increased to 4.63 ± 1.77 µm. The fiber beads, irregular shape, and uneven distribution of diameters of the fibers were observed in the membranes with the high drug loadings, likely due to insoluble drug particles in the spinning solutions and the increased surface tension of the spinning solution [2].

3.2 Structural analysis

Characteristic peaks for silk I structure around 1652 cm⁻¹ (Amide I), 1543 cm⁻¹ (Amide II), 1242 cm⁻¹ (Amide III) and 669 cm⁻¹ (Amide V), and silk II peaks around 1626 cm⁻¹ (Amide I), 1532 cm⁻¹ (Amide II), 1236 cm⁻¹ (Amide III) and 696 cm⁻¹ (Amide V) have been reported [34, 35]. As shown in Fig. 3B,
the major peaks at 1542.3 cm\(^{-1}\) and 1648.2 cm\(^{-1}\) that accompany \(\alpha\)-helix and random coil structures were found in SF membranes (curve a). The characteristic peaks at 1520.7 cm\(^{-1}\) and 1629.5 cm\(^{-1}\) indicated the presence of \(\beta\)-sheet structure in the SF/PEG membrane (curve b). This is consistent with our previous observations that addition of PEG-400 promoted a structural transformation from \(\alpha\)-helix and random coil dominated material to \(\beta\)-sheet dominated structure in the material [36]. For the drug-loaded membranes of 0.15/0.25, 0.3/0.5 and 0.45/0.75% by weight of CUR/5-FU (curves c-e), the characteristic peaks of CUR at 1447.5 cm\(^{-1}\), 1170.6 cm\(^{-1}\) and 955.1 cm\(^{-1}\), and 5-FU at 2932.7 cm\(^{-1}\), 2875.7 cm\(^{-1}\), 1423.4 cm\(^{-1}\) and 551.9 cm\(^{-1}\) were identified, suggesting that the dual drugs were encapsulated in the membranes with chemical structures still present. The result also showed that the addition of drugs did not influence the secondary structures of SF.

The secondary structure of SF (a) and SF/PEG (b) membranes were mainly alpha helical, with a higher content than that in the drug-loaded SF membranes (c-e) (**, \(P<0.05\)) (Fig 3C). The beta sheet content of the drug-loaded SF membranes was significantly higher than that of the control group SF(a) and SF/PEG (b) (***, \(P<0.01\)), indicating that drug loading promoted the formation of beta sheet. The beta sheet content in the drug loaded membranes reached 40.44% when the proportion of CUR/5-FU was increased to 0.3/0.5 wt%, significantly higher than that of 0.15/0.25 wt% group c (34.23%) and 0.45/0.75 wt% group e (34.73%). This increase was likely because the hydrophobic CUR binds to the hydrophobic region of SF, which induced the secondary structure of SF to transition to beta sheet, with the main structure of the drug-loaded membrane as silk II after adding CUR/5-FU. This is consistent with the XRD analysis (Fig. 3D). The content of beta sheet increased from 34.23% to 40.44% when the proportion of CUR/5-FU was increased from 0.15/0.25 wt% (c) to 0.3/0.5 wt% (d). However, as the drug concentration was increased, the content of beta sheet decreased, possibly due to the negative effect of increase of 5-FU loading content that easily binds to the hydrophilic region of SF.
According to previous studies on silk crystal structures using WAXD analysis, the main reflection peaks located at 12.1°, 19.8°, 24.1°, 28.5° and 33.3° were ascribed to the silk I structure, and those located at 9.1°, 18.8°, and 20.5° were ascribed to the silk II structure [16]. Fig. 3D shows the transition of the reflection peak at 23.1° in the SF membrane to 20.1° in the SF/PEG membrane, indicating that the addition of PEG-400 induced the transformation of SF membrane from silk I to silk II structure, consistent with the FT-IR observations. The reflection peaks of three CUR/5-FU loaded membranes were all at 20.7°, demonstrating the presence of silk II structure. Thus, in line with the FT-IR observations, the X-ray diffraction data confirmed that the incorporation of the dual drugs in the membrane did not significantly influence the secondary structure and crystallization of the silk protein in the membranes. Maintenance of a high content of crystalline β-sheet structure would increase mechanical strength, sustain drug release, and prevent material degradation, thus benefiting in vivo applications.

3.3 Pore size distribution

The pore size of a membrane is important for fluid permeability and cellular behavior. Pores provide sufficient space for cells ingrowth, thus promoting the release of drugs from the interface of the material into the surrounding tissues [37]. According to literatures, there is a close relationship between fiber diameter and pore size distribution [38]. The pore size distributions of electrospun membranes were examined using capillary flow porometry (Fig. 3E). The smallest pore size and fiber diameter of the SF/PEG membranes were 23.1 ± 0.5 μm and 1.45 ± 0.41 μm, respectively. With the increase of drug loading from 0.15/0.25 wt% to 0.3/0.5 wt%, the pore size and fiber diameter of the CUR/5-FU membranes increased from 24.2 ± 0.5 μm and 1.73 ± 0.54 μm to 31.1 ± 0.5 μm and 2.75 ± 0.78 μm, respectively. When the drug loadings were increased to 0.45/0.75 wt%, the pore size and fiber diameter of the membranes increased to 42.7 ± 0.5 μm and 4.63 ± 1.77 μm, respectively, but uneven fiber structure and beads were found in the membranes, consistent with reports in the literature [38].
3.4 Hydrophilic test

The hydrophilicity of drug-loaded membranes is important because drug delivery often comes in contact with various biological fluids during use [39, 40]. CUR/5-FU in the hydrophilic drug-loaded membranes distributed readily in the extracellular matrix (ECM) and diffused efficiently through intercellular spaces, so releasing anti-tumor drugs after arrival at tumor sites could significantly facilitate deep tumor penetration [41]. As shown in Fig. 4 and Table 1, the SF membrane showed a hydrophobic surface with a water contact angle (WCA) of $134.4 \pm 0.2^\circ$ at the beginning of analysis, and the WCA gradually decreased as the contact time was prolonged. In contrast, the SF/PEG membranes showed a hydrophilic surface with a contact angle of $63.9 \pm 0.5^\circ$ at the beginning of the analysis, and the contact angle decreased to $41.3 \pm 0.5^\circ$ after 20 seconds, much lower than the pure SF membrane. This result indicated that the addition of PEG-400 improved hydrophilicity of the membranes. The CUR/5-FU loaded membrane showed a more hydrophobic surface as compared to the pure SF and SF/PEG membranes, indicating that the addition of CUR, which is hydrophobic, increased hydrophobicity of the drug-loaded membranes, consistent with that reported in the literatures [43, 44]. Such hydrophilicity will be useful for the in vivo applications of stents because drug-loaded membranes provide novel hydrophilic drug delivery with improved functional properties, such as mucus permeation and improved cellular uptake, which lead to a raised bioavailability of the hydrophilic drug in the loaded membranes [42].

3.5 Drug release

As shown in Fig. 3F, the concentrations of the dual drugs in the release medium increased with the increase of drug loading in the membranes. The cumulative release rate increased with increased loading of CUR and 5-FU in the membranes. The drug-loaded membranes showed a fast release profile within 72 hrs and then release remained stable during 210 - 400 hrs. Particularly, the cumulative release of 5-FU reached 95.63% at 96 hrs, while the CUR reached this percentage at 210 hrs. This is due to the water
solubility of 5-FU, is higher than that of CUR. For all three membranes with different drug loadings, CUR and 5-FU were completely released within 400 hrs. It is likely that the fast release at the beginning was due to the diffusion of free drug from the nanofibrous membranes, while residual drugs inside the membranes were responsible for the sustained release along with the material degradation [45, 46].

3.6 *In vitro* anti-tumor capability and cytotoxicity of drug-loaded membranes

In order to evaluate the time-dependent *in vitro* anti-tumor effect of the CUR/5-FU loaded membranes, HCT116 cells were treated with pure drugs at their IC$_{50}$ concentration or drug-loaded membranes for 120 hrs, and cell viabilities were determined at different time points (Fig. 5A). After 12 hrs, cell viability of the 5-FU group was lower than those of CUR and CUR/5-FU groups. This could partly be because the addition of CUR reduced the inhibitive effect of 5-FU on HCT116 cells during the initial stages of exposure. As the treatments prolonged, the viability of HCT116 cells for the CUR, 5-FU and CUR/5-FU pure drug groups decreased rapidly, likely due to increased drug uptake efficiency by the cells [47, 48]. After 120 hrs treatment, cell viabilities of these groups were 50.01%, 50.02% and 21.72%, respectively. The drug-loaded (0.3/0.5 wt%) membranes groups exhibited a more rapid decrease of cell viability as compared to the pure drug groups, with 8.70 ± 0.39% after 120 hrs treatment, significantly lower than that of CUR/5-FU pure drug groups (21.26 ± 0.90%) at the same time point (p<0.05). These results suggest that the drug-encapsulated SF membranes exhibited more efficient and more sustained anti-tumor effects as compared to the pure drugs, likely due to the stable and long term exposure of drugs in the drug-loaded membrane groups. The long-term *in vitro* toxic effects of CUR/5-FU loaded membranes were evaluated using non-cancerous NCM460 cells. As shown in Fig. 4B, the trend of cell viability change of NCM460 cells treated with experimental samples was similar to that of HCT116 cells. NCM460 cells co-cultured with the SF groups exhibited normal growth after cell adhesion, and the cell viability was close to the level of the control group. For drug-loaded (0.3/0.5 wt%) membranes, cell...
viability narrowed to 9.99 ± 0.99% at 120 hrs from 48.03 ± 0.91% at 12 hrs because of slow and controlled release of CUR/5-FU.

3.7 Cell cycle and apoptosis analysis

Cell cycle anomalies induced by DNA replication errors are often observed in different types of cell damage [49]. DNA damage caused by chemo-drugs, such as 5-FU, interrupt cell cycle progression, leading to S phase arrest [50]. HCT116 cells treated with the CUR/5-FU combination treatment had a higher percentage of S phase cells (35.63%) as compared to the single treatment group (CUR: 31.52% and 5-FU: 33.45%) after 24 hrs treatment (Fig. 5C). This result indicated a synergistic effect of the combination treatment, which might have promoted S phase arrest. CUR/5-FU 0.3/0.5% membrane treatment induced a stronger effect as compared to the solution combination treatment, with the percentage of S phase cells reaching 54.69% after 48 hrs of treatment. These data suggest that the drug-loaded SF membranes had a higher anti-tumor effect as compared to the control of drugs in a soluble form, demonstrating the capability of SF material as a carrier to provide controlled drug release. The effect of CUR and 5-FU on the cell cycle of NCM460 cells was also determined. NCM460 cells (Fig. 5D) showed S phase arrest after 48 hrs treatment, similar to HCT116 cells.

We next performed Annexin-V/PI double staining to evaluate apoptosis-induced cell suicide, which may be another anti-tumor mechanism in addition to cell cycle arrest [51]. Annexin V (aV) reacted with phosphatidylserine (PS) was used as a marker of apoptosis. Presidium iodide (PI), which was utilized to detect plasma membrane integrity, was employed to detect necrotic cell death. Cell status was determined based on the percentage of aV−/Vesidium iodideaV+/PI− (necrotic), aV+/PI− (apoptotic), and aV+/PI+ (late apoptotic). HCT116 and NCM460 cells were stained and the apoptosis status of cells treated for 24 hrs and 48 hrs are shown in Fig. 5E and F. In the SF-treated group, very few apoptotic cells were found, indicating the silk membranes had excellent cytocompatibility and promoted the proliferation of both HCT116 and NCM460 cells. The single treatment with either CUR or 5-FU after 48
hrs induced a similar percentage (25.54% and 28.94%) of apoptotic HCT116 cells, respectively. In line with cell cycle analysis results, the combination treatment of CUR/5-FU presented higher apoptosis (38.85%) after 48 hrs. The controlled release CUR/5-FU (0.3/0.5 wt%) loaded membranes demonstrated the best anti-tumor effects, reaching an apoptotic cell percentage of 42.94%, consistent with the results from cell cycle analysis. Similar results were found for the NCM460 cells, indicating that CUR and 5-FU inevitably induced the apoptosis of non-cancerous epithelial cells. The ratios between 5-FU/CUR or other chemotherapy drug combinations will need to be optimized in the future to minimize toxicity to non-cancerous epithelial cells.

Based on the results of cell cycle and apoptosis, we found that CUR/5-FU loaded membranes had a higher anti-cancer effect compared to the single drug-loaded membranes. These results were similar to our previous study on 5-FU-loaded poly-L-lactide membranes for the treatment of colorectal cancer [2], which indicated that the mechanisms of inhibition of both HCT116 and NCM460 cells were due to increased apoptosis associated with cell cycle arrest. The mechanism of CUR/5-FU induced cell apoptosis could be due to the inhibition of Stat3 and NF-κB signaling pathways.

### 3.8 Effect on drug resistance inhibition

Several signaling pathways, such as Stat3 and NF-κB, play important roles in drug resistance of colorectal cancer cells after chemo-therapies, such as with 5-FU [52, 53]. NF-κB is a crucial regulator of many physiological and pathophysiological processes including control of inflammation and cancer progression. Stat3 relays signals from activated receptors in the plasma membrane to the nucleus, where it accumulates and regulates target gene expression [54]. Combination treatment with drugs targeting these pathways presents synergistic effects. The protein expressions of P-Stat3 and P-P65 in HCT116 and NCM460 cells with the treatment of pure drugs and drug-loaded SF membranes were analyzed (Fig. 5G-J). The expression of P-Stat3 and P-P65 decreased in the single CUR or 5-FU-treated groups as compared to either the control group or the SF group, suggesting that the CUR or 5-FU treatments could
inhibit drug resistance. The CUR/5-FU treatment showed a stronger drug resistance-inhibiting effect, as the expression of both proteins was lower than the single CUR or 5-FU treatments. The strongest inhibition effect, especially on Stat3 signaling pathway, was observed in the SF membranes loaded with CUR/5-FU (0.3/0.5 wt%). These data indicate that the SF membranes as a delivery carrier may promote the anti-tumor effect of CUR and 5-FU through regulating Stat3 and NF-κB pathways. These results indicated that the Stat3 and NF-κB signaling pathway in HCT116 and NCM460 cells was suppressed due to the CUR/5-FU released from the drug-loaded SF membranes.

3.9 In vivo study of the anti-tumor effect

For toxicity analysis, the median lethal dose (LD$_{50}$) was used to evaluate acute toxicity as approved by the FDA in our previous study [55]. The control and SF membrane groups showed no difference in terms of tumor volumes; both increased to approximately 350% after 12 days post-surgery (Fig. 6B, left). The body weight changes of mice were measured every two days. No significant difference was found between the control and SF-treated groups (Fig. 6B, right). A significant decline of body weight was observed in the other three drug-treated groups from day 2, but no significant difference was found between these groups. These data indicated that the SF membranes as a drug delivery carrier was safe for use in vivo, without causing severe side effects. After the mice were sacrificed at day 12, the tumors were removed and processed for microscopy (Fig. 6C, left). The tumor volumes of the CUR/5-FU LD$_{50}$ combination group were 139.25±9.59% compared to original volume after 12 days, smaller than that of the single 5-FU LD$_{50}$ treatment group (178.16±10.89%) as well as the control and SF membrane groups, indicating a synergistic anti-tumor effect for the combination treatment, consistent with the in vitro results. The strongest anti-tumor effect was found in the group of CUR/5-FU (0.3/0.5%) loaded SF membranes; the tumor volume decreased to 99.97±8.76% of initial volume. These data indicated that the SF membranes with controlled release features extended the duration for drugs to be absorbed by the
tumor cells, resulting in improved anti-tumor effects. The expression of P-Stat3 and P-P65 in the tumors was analyzed, and the results were similar to that obtained in the in vitro study (Fig. 6C, right).

Representative images for histopathology are illustrated in Fig. 6D. Partial necrosis was found in the control and SF groups, mainly because of the rapid tumor growth. Single drug treatments with 5-FU LD50 and the CUR/5-FU LD50 treatment induced both necrosis and apoptosis, indicating that necrosis of intestinal cells was an unavoidable side effect of the localized high-concentration of 5-FU or CUR/5-FU treatment. However, CUR/5-FU (0.3/0.5%) loaded membranes induced more apoptosis, while few necrotic cells were observed. The results showed that the drug-loaded membranes provided more efficient and sustained anti-tumor effects, mainly attributed to the drug-controlled release properties. Decreased levels of P-Stat3 were observed when treated with single 5-FU LD50 or the CUR/5-FU combination. The group of CUR/5-FU (0.3/0.5 wt%) loaded SF membranes indicated the lowest level of P-Stat3 (Fig. 6E). This result corresponded to the previous in vitro cell signaling analysis (Fig. 5G), suggesting that the drug-loaded membrane could provide improved induction of apoptosis in vivo, which might be associated with the inhibited Stat3 signaling pathway.

4. Conclusions

CUR and 5-FU were dissolved with PEG in SF solution at three concentrations (0.15/0.25%, 0.3/0.5% and 0.45/0.75% by weight to the SF solution), and the solutions were electrospun onto weft-knitted SF/PDO stents. The results showed that the incorporation of the dual drugs in the membranes did not significantly influence secondary structure and crystallization of the silk protein in the membranes. The drug-loaded membranes showed burst-release behavior within 72 hours and subsequently the release kinetics remained stable during 210-400 hrs. CUR/5-FU loaded membranes showed better anti-tumor effects. This can be attributed to cell cycle arrest in the S phase in association with induced apoptosis in tumor cells by blocking Stat3 and NF-κB signaling pathways. Furthermore, in vivo, the implanted
CUR/5-FU loaded membranes showed the smallest tumor volume and lightest tumor weight, and induced more apoptosis with few necrotic cells observed. Therefore, the weft-knitted SF/PDO stents coated with CUR/5-FU loaded membranes have potential in the management of cancer progress and drug-resistance of tumor cells.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (51603140), Natural Science Foundation of Jiangsu Province (BK20150372), and “National Key R&D Program of China (No. 2017YFC1308800)”. The authors would like to thank the support of China Postdoctoral Science Foundation, University Science Research Project of Jiangsu Province (16KJB540003) and Key Industry Technology Innovation, Science and Technology Project of Suzhou (SYG201638), and Sino-Germany Joint Project (GZ1094).

Author contributions

Xusheng Xie and Xiaobin Zheng designed the work, prepared the biomaterials and wrote the manuscript. Zhifen Han with the background of traditional Chinese medicine characterized the drugs and identified the anti-tumor mechanism. Yufeng Chen, Bin Zheng and Xiaowen He from the gastrointestinal hospital assisted with cell and animal experiments. Zhaozhu Zheng and Yongfeng Wang did the materials characterization and scientific analysis. David L Kaplan and Yi Li instructed the writing including layout, interpretation and English. Gang Li, Xiaoqin Wang and Ping Lan are the main principle investigators of this cooperation and instructed the whole process of this study including design of experiment, preparation and biological evaluation and so on since this is an interdisciplinary project.

Disclosure

The authors have nothing to disclose regarding the conflict of interest.
**Figures**

Fig. 1. Schematic of mechanisms and processes of drug-loaded stent deployment and functions for the treatment of colorectal cancer; (a) deflated balloon catheter and compressed drug-loaded stent are inserted into the stenosis site; (b) inflated balloon expands the stent and compresses the tumor to restore the intestinal lumen; (c) stent-widened intestine; (d) and (e) the drugs are released from the coating membrane and the tumor is treated locally.
Fig. 2. Experimental design: (a): PDO polymer was synthesized by a conventional bulk ring-opening polymerization method; (b): PDO monofilament was weft-knitted into a tubular stent; (c): the principle diagram and photos of the modified electro spinning machine; (d): the prepared stent with drug-loaded coating membrane; (e) and (f): anti-tumour effect of the drug-loaded membrane was examined \textit{in vitro} and \textit{in vivo} using HCT116, NCM460 cells and BALB/c nude mice.
Fig. 3. (A) Micrographs and fiber diameter distribution of drug-loaded membranes; FT-IR spectrums (B), WAXD spectrums (C), Pore size distribution (D) and Images of WCA (E) of the membranes: (A-E, a-e)
represent SF, SF/PEG and three groups of SF/PEG/drug fibrous membranes with 0.15/0.25, 0.3/0.5 and 0.45/0.75 wt% of CUR/5-FU, respectively. *In vitro* drug release profiles (F) of three SF/PEG/drug membranes with 0.15/0.25, 0.3/0.5 and 0.45/0.75 wt% of CUR/5-FU loadings; Data presented is the mean (±) standard deviation of at least four measurements (n = 4).

![Images of WCA of SF, SF/PEG and three drug membrane groups of SF/PEG/drug fibrous membranes with 0.15/0.25, 0.3/0.5 and 0.45/0.75 wt% of CUR/5-FU.](image)

**Fig. 4.** Images of WCA of SF, SF/PEG and three drug membrane groups of SF/PEG/drug fibrous membranes with 0.15/0.25, 0.3/0.5 and 0.45/0.75 wt% of CUR/5-FU.
Fig. 5. (A, B) Time-dependent in vitro anti-cancer effect of drug-loaded membranes on HCT116 cells and cytotoxicity on NCM460 cells within 120 hrs. Quantitative analysis of Cell cycle (C, D) and Apoptotic progression (E, F) of HCT116 and NCM460 cells co-cultured with experimental samples at
24 and 48 hrs. Western blot of GAPDH, NF-κB (P-P65) and P-Stat3 protein levels in HCT116 and
NCM460 cells co-cultured with experimental samples at 24 and 48 hrs (G, I); expression of P-Stat3
protein levels in cell nucleus morphology determined by goat anti-rabbit IgG (green) and DAPI (blue)
(H, J). All the data was obtained from at least three independent experiments. The statistical significance
is expressed as ***p < 0.001, **p < 0.01, *p < 0.05.
Fig. 6. (A) Operative procedure for membrane implantation into the tumor; (a): the mouse was given general anesthesia induced by intraperitoneal injection of pentobarbital sodium (30 μg/g body weight);
(b): the drug membrane was implanted into the tumor. *In vivo* investigation of tumor inhibition effects of the CUR/5-FU membrane: (B) tumor growth curves and body weight change ratios of mice treated by different groups during the experimental periods; (C) macroscopic images of exposed tumor; and Western blot of tumor extracts in experimental mice. Solid tumor histopathological images on apoptosis and necrosis (D) and immunohistochemical staining images of P-Stat3 (E) for the tumors in mice treated with blank control; pure SF membrane; 5-FU and CUR/5-FU solution (LD<sub>50</sub>), CUR/5-FU membrane (0.30/0.50 wt%) after 12 days. The apoptotic cells showed well maintained integrity of nucleus and cytoplasm while necrotic cells displayed dispersed basophilic spots within weakly eosinophilic cytoplasm. Black arrows indicate positive P-Stat3 staining.
**Supplemental Data**

In order to determine cell morphology, the nucleus and cytoskeleton of HCT116 and NCM460 cells were visualized (Supplemental Fig. 1A and B). In line with the determination of total cell metabolic activity, both cell lines treated with SF alone showed similar features to those in the control group, with cells spreading and growing to a high density. Either CUR or 5-FU treatment inhibited cell growth of both cell lines or the combination treatment further enhanced the inhibitory effect. Consistent with the results from MTS assay, treatments with CUR/5-FU (0.3/0.5 wt%) loaded membranes significantly reduced the growth rate and numbers of both cell lines. In addition, these reductions were even lower than CUR/5-FU group. These data indicate that drug-loaded membranes could be used as a material to inhibit cancer cell growth, although non-cancerous cells were inevitably affected to some extent.

The results of cell cycle and FACS distributions (%) of apoptotic HCT116 and NCM460 cells co-cultured with experimental samples at 24 and 48 hrs are shown in Supplemental Fig 1C and D. The inhibition effect on S phase arrest was similar between NCM460 and HCT116 cells after 48 hrs treatment.
Supplemental Figure 1. (A, B) Microscopic images of HCT116 and NCM460 cells co-cultured with experimental samples at 24 and 48 hrs with DAPI (blue) and rhodamine-phalloidin (red) staining; (C, D) Cell cycle and FACS distributions (%) of apoptotic HCT116 and NCM460 cells co-cultured with experimental samples at 24 and 48 hrs. All the data was obtained from at least three independent experiments. The statistical significance is expressed as ***p < 0.001, **p < 0.01, *p < 0.05.
Table

Table 1. WCA of SF, SF/PEG and three groups of SF/PEG/drug loaded membranes.

<table>
<thead>
<tr>
<th>Samples</th>
<th>Time</th>
<th>0 s</th>
<th>5 s</th>
<th>20 s</th>
<th>30 s</th>
<th>60 s</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF</td>
<td>0 s</td>
<td>134.4° ± 0.6°</td>
<td>125.8° ± 0.6°</td>
<td>79.2° ± 0.1°</td>
<td>37.1° ± 0.2°</td>
<td>22.4° ± 0.3°</td>
</tr>
<tr>
<td>SF/PEG</td>
<td>5 s</td>
<td>63.9° ± 0.4°</td>
<td>48.7° ± 0.2°</td>
<td>41.3° ± 0.3°</td>
<td>40.3° ± 0.3°</td>
<td>27.9° ± 0.1°</td>
</tr>
<tr>
<td>0.15/0.25 wt%</td>
<td>20 s</td>
<td>108.6° ± 0.5°</td>
<td>102.3° ± 0.5°</td>
<td>96.7° ± 0.4°</td>
<td>86.3° ± 0.4°</td>
<td>63.6° ± 0.4°</td>
</tr>
<tr>
<td>0.15/0.25 wt%</td>
<td>30 s</td>
<td>158.2° ± 0.7°</td>
<td>147.9° ± 0.4°</td>
<td>134.9° ± 0.3°</td>
<td>103.2° ± 0.3°</td>
<td>59.3° ± 0.3°</td>
</tr>
<tr>
<td>0.45/0.75 wt%</td>
<td>60 s</td>
<td>162.7° ± 0.5°</td>
<td>151.3° ± 0.6°</td>
<td>82.1° ± 0.7°</td>
<td>79.3° ± 0.5°</td>
<td>32.7° ± 0.2°</td>
</tr>
</tbody>
</table>
References


Table 1. WCA of SF, SF/PEG and three groups of SF/PEG/drug loaded membranes.

<table>
<thead>
<tr>
<th>Samples</th>
<th>Time</th>
<th>0 s</th>
<th>5 s</th>
<th>20 s</th>
<th>30 s</th>
<th>60 s</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF</td>
<td>134.4° ± 0.6°</td>
<td>125.8° ± 0.6°</td>
<td>79.2° ± 0.1°</td>
<td>37.1° ± 0.2°</td>
<td>22.4° ± 0.3°</td>
<td></td>
</tr>
<tr>
<td>SF/PEG</td>
<td>63.9° ± 0.4°</td>
<td>48.7° ± 0.2°</td>
<td>41.3° ± 0.3°</td>
<td>40.3° ± 0.3°</td>
<td>27.9° ± 0.1°</td>
<td></td>
</tr>
<tr>
<td>0.15/0.25 wt%</td>
<td>108.6° ± 0.5°</td>
<td>102.3° ± 0.5°</td>
<td>96.7° ± 0.4°</td>
<td>86.3° ± 0.4°</td>
<td>63.6° ± 0.4°</td>
<td></td>
</tr>
<tr>
<td>0.15/0.25 wt%</td>
<td>158.2° ± 0.7°</td>
<td>147.9° ± 0.4°</td>
<td>134.9° ± 0.3°</td>
<td>103.2° ± 0.3°</td>
<td>59.3° ± 0.3°</td>
<td></td>
</tr>
<tr>
<td>0.45/0.75 wt%</td>
<td>162.7° ± 0.5°</td>
<td>151.3° ± 0.6°</td>
<td>82.1° ± 0.7°</td>
<td>79.3° ± 0.5°</td>
<td>32.7° ± 0.2°</td>
<td></td>
</tr>
</tbody>
</table>
Figure B

Cell Viability (%) vs. Time (Hour) for different treatments:
- Control
- SF
- CUR, IC50
- 5-FU, IC50
- CUR/5-FU, IC50
- CUR/5-FU, 0.15/0.25%
- CUR/5-FU, 0.3/0.5%
- CUR/5-FU, 0.45/0.75%

NCM-460 cell viability is measured at various time points (12, 24, 48, 72, 96, 120 hours) showing significant differences among the treatments indicated by asterisks (** and ***).
<table>
<thead>
<tr>
<th></th>
<th>Ctrl</th>
<th>SF</th>
<th>CUR.IC50</th>
<th>5-FU.IC50</th>
<th>CUR/5-FUIC50</th>
<th>CUR/5-FU 0.3/0.5%</th>
</tr>
</thead>
<tbody>
<tr>
<td>H</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[Images of cellular samples for each condition are shown, with measurements marked as 50 µm.]
Figure

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>SF</th>
<th>CUR.IC50</th>
<th>5-FU.IC50</th>
<th>CUR/5-FU IC50</th>
<th>CUR/5-FU 0.3/0.5%</th>
</tr>
</thead>
<tbody>
<tr>
<td>48-hour</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCT-116</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24-hour</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Supplementary Files
Click here to download Supplementary Files: Relevant data - subgraphs.rar